Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management

Christopher Luzzio, MD; Kerstin Hellwig, MD

June 30, 2022

The potential benefits and risks of the use of DMTs should be carefully considered for each patient who is pregnant or is planning to become pregnant.

Teriflunomide belongs to FDA pregnancy category X (after 2015, the FDA adopted a more descriptive system to communicate pregnancy risk information), owing to its embryotoxicity and teratogenicity, and it should therefore be avoided in these patients. Because teriflunomide is present in the blood for several months after discontinuation, women who use this drug but are planning pregnancy need to undergo an accelerated elimination procedure with cholestyramine or charcoal. The teratogenicity potential of cladribine also limits its use.

Learn more about MS in pregnancy.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Christopher Luzzio, Kerstin Hellwig. Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management - Medscape - Jun 30, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.